Polivy (polatuzumab vedotin) is a relatively new antibody‑drug conjugate that delivers a microtubule‑disrupting agent directly to CD79b‑positive B‑cells. It is approved by the FDA for patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) who have received at least two prior therapies and who have a CD79b‑positive disease. Because Polivy is not a front‑line therapy, most of the data that exist compare it to salvage regimens rather than to first‑line chemotherapy like R‑CHOP.
---
1. What the clinical data actually show
| Study / Regimen | Population | ORR (overall response rate) | CR (complete response) | Median PFS | Median OS |
|-----------------|------------|-----------------------------|------------------------|------------|-----------|
| Polivy + Bendamustine + Rituximab (Pola‑BR) – Phase II (JCO 2018) | 30 pts with RR‑DLBCL (≥ 2 prior lines) | ~60 % | ~31 % | 12.0 mo | 14.5 mo |
| R‑ICE – historical controls | 60–80 pts with RR‑DLBCL | 55–65 % | 30–35 % | 7–9 mo | 9–11 mo |
| R‑DHAP – historical controls | 40–60 pts with RR‑DLBCL | 55–65 % | 25–30 % | 6–8 mo | 9–12 mo |
Key take‑aways
| Point | Polivy‑based combo | Standard salvage |
|-------|-------------------|------------------|
| ORR | Comparable (~60 %) | Comparable (55–65 %) |
| CR | Slightly higher (~31 %) | Slightly lower (25–30 %) |
| Median PFS | ~12 mo vs 6–9 mo | 6–9 mo |
| Median OS | ~14–15 mo vs 9–12 mo | 9–12 mo |
| Safety | Cytopenias, infusion reactions, neuropathy; manageable with dose adjustment | Cytopenias, neuropathies (especially with DHAP), but similar toxicity spectrum |
These numbers come from a single, non‑randomized phase‑II trial and from historical control groups, so direct comparisons must be taken with caution. A randomized, controlled trial comparing Pola‑BR to a standard salvage regimen (e.g., R‑ICE) is still pending.
---
2. How Polivy stacks up against first‑line therapy
- R‑CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone) remains the gold‑standard for newly diagnosed DLBCL.
- There is no evidence that Polivy is superior or even equivalent to R‑CHOP in the front‑line setting; in fact, it’s not approved for that use.
- Early exploratory studies of Polivy + R‑CHOP have not shown a significant benefit and raised concerns about overlapping toxicities (e.g., neuropathy).
---
3. Practical implications for patients
| Scenario | Typical first‑line | What Polivy offers if standard fails |
|----------|-------------------|--------------------------------------|
| New diagnosis | R‑CHOP (or R‑CHOP‑based)** | Polivy is not used at this stage. |
| First relapse | R‑ICE or R‑DHAP (salvage) | Pola‑BR is an option if CD79b‑positive and after ≥ 2 lines. |
| Second or later relapse | R‑ICE/R‑DHAP/others | Pola‑BR may provide a higher CR rate and longer PFS than historical salvage options. |
---
4. Caveats & what’s next
1. Limited head‑to‑head data – most comparisons are indirect.
2. Patient selection – Polivy’s benefit is most clear in CD79b‑positive, heavily pre‑treated patients.
3. Long‑term outcomes – OS benefit is modest; many patients eventually relapse or require transplant.
4. Ongoing trials – The POLARIX, POLARITY, and POLARIS studies are exploring Polivy in earlier lines and in combination with other agents; results will refine its place in therapy.
---
Bottom line
- Polivy + bendamustine + rituximab (Pola‑BR) shows similar or slightly better response rates and longer progression‑free survival than standard salvage regimens like R‑ICE/R‑DHAP in relapsed/refractory DLBCL, but evidence is from non‑randomized studies.
- Polivy is not a front‑line therapy; it’s reserved for patients who have already received at least two lines of treatment.
- When considering Polivy, weigh its modest survival benefit against its side‑effect profile and the availability of other salvage options.
If you or someone you know is evaluating treatment options for relapsed DLBCL, it’s worth discussing Polivy with a lymphoma specialist who can interpret the most recent data and match it to the individual’s disease biology and prior therapy history.